Recent Updates
Recently added Catalysts
SCYX

SCYNEXIS, Inc. to Present at RBC Capital Markets 2015 Healthcare Conference

Key Takeaway: RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' CEO and President, will present at the RBC Capital Markets 2015 Healthcare Conference at the

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
12.1%
average across 3 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Ibrexafungerp
Phase 3 · Vulvovaginal Candidiasis

Full Press Release Details

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' CEO and President, will present at the RBC Capital Markets 2015 Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, February 24, 2015, at 3:05 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for three months following the presentation.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
Last updated: Feb 19, 2015